Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction

Osimertinib, a third‐generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), provides marked clinical benefit for patients with EGFR‐activating mutations. Unfortunately, limited treatments exist for patients who acquire osimertinib resistance. We observed two ‘...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Rui, Hao, Shuai, Lu, Conghua, Zhang, Chong, Lin, Caiyu, Li, Li, Wang, Yubo, Hu, Chen, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266273/
https://www.ncbi.nlm.nih.gov/pubmed/32239624
http://dx.doi.org/10.1002/1878-0261.12682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266273/
https://www.ncbi.nlm.nih.gov/pubmed/32239624
http://dx.doi.org/10.1002/1878-0261.12682

Ejemplares similares